ArticleRadiology case reports2026
Extranodal marginal zone lymphoma presenting as a skin-based breast finding detected on screening mammography.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal marginal zone lymphoma (EMZL) of the breast is rare and may mimic benign skin lesions at screening. We report a 72-year-old woman with a new superficial mass on screening mammography. Tangential views and ultrasound localized the abnormality to the dermis/subdermis, and ultrasound-guided biopsy revealed a low-grade B cell lymphoma with plasmacytic differentiation. Staging with PET/CT, a skin punch biopsy of a cutaneous shoulder lesion, and bone marrow biopsy confirmed disseminated disease, consistent with stage IV EMZL. This case underscores practical imaging steps, strategies, and differential diagnostic considerations to correctly identify skin-based findings and avoid misclassification. When appearances are new or atypical, particularly without a visible cutaneous correlate, tissue sampling is warranted to exclude malignancy, including dermal lymphoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.